Meeting
2015 ASCO Annual Meeting
Implications of high tumor infiltrating lymphocytes (TIL) in HER2-positive and triple-negative breast cancer (TNBC).
Authors
Vassiliki Kotoula
Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece
Vassiliki Kotoula , Kyriakos Chatzopoulos , Sotiris Lakis , Zoi Alexopoulou , Eleni Timotheadou , Flora Zagouri , George E. Pentheroudakis , Helen Gogas , Eleni P. Galani , Eleftheria Tsolaki , Sofia Chrisafi , Angelos Koutras , Gerasimos Aravantinos , Pavlos Papakostas , Paris A. Kosmidis , Dimitrios G. Pectasides , George Fountzilas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 592)
DOI
10.1200/jco.2015.33.15_suppl.592
Abstract #
592
Poster Bd #
81
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Trends in breast cancer mortality according to molecular subtypes: A population-based study.
First Author: Yunan Han
Poster
2017 ASCO Annual Meeting
Trop2 gene expression (Trop2e) in primary breast cancer (BC): Correlations with clinical and tumor characteristics.
First Author: Neelima Vidula
Poster
2016 ASCO Annual Meeting
Values of tumor-infiltrating lymphocytes (TILs), CD8+ TILs, and PDL-1 for predicting pathological complete response and prognosis in HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab.
First Author: Sasagu Kurozumi
Poster
2016 ASCO Annual Meeting
Association between distinct intratumoral and stromal tumor infiltrating immune cells and pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
First Author: Lucia Gonzalez-Cortijo